OligoTune Ltd is dedicated to bringing new hope and improved outcomes to cancer patients through its pioneering RNA technology. Our mission is to create effective, patient-centred treatments that directly activate the body’s immune system within the tumour microenvironment. We are committed to providing innovative therapies that address the urgent needs of patients, especially those with therapy-resistant solid tumours.
Our technology leverages small interfering RNA (siRNA) to reprogram the Tumour Immune Microenvironment (TIME), targeting key immunosuppressive factors. This approach allows us to address multiple resistance mechanisms simultaneously and target previously undruggable targets. Our solution is flexible, safe, and capable of multiplexing, offering precise and effective modulation of the immune system.
OligoTune is actively developing drug candidates and collaborating with partners to advance our mission. With a strong commitment to research and development, we focus on delivering innovative and patient-centred cancer therapies. Through our groundbreaking work and partnerships, we aim to transform cancer treatment and bring new hope to patients around the world.
-
Industry
-
Biotechnology Research
-
Company size
-
2-10 employees
-
Type
-
Privately Held
-
Founded
-
2024
